{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:18:21Z","timestamp":1776287901818,"version":"3.50.1"},"reference-count":101,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.ecl.2007.07.001","type":"journal-article","created":{"date-parts":[[2008,1,9]],"date-time":"2008-01-09T18:43:14Z","timestamp":1199904194000},"page":"1051-1066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["Interferon Alpha Treatment and Thyroid Dysfunction"],"prefix":"10.1016","volume":"36","author":[{"given":"Yaron","family":"Tomer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason T.","family":"Blackard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagako","family":"Akeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ecl.2007.07.001_bib1","first-page":"2489","article-title":"Biological properties of recombinant alpha interferons: 40th anniversary of the discovery of interferons","volume":"58","author":"Pfeffer","year":"1998","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ecl.2007.07.001_bib2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00001622-200311000-00005","article-title":"Interferons: mechanisms of action and clinical applications","volume":"15","author":"Parmar","year":"2003","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2007.07.001_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1634\/theoncologist.6-1-34","article-title":"Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities","volume":"6","author":"Jonasch","year":"2001","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.ecl.2007.07.001_bib4","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jama.1991.03470100067035","article-title":"The interferons. Mechanisms of action and clinical applications","volume":"266","author":"Baron","year":"1991","journal-title":"JAMA"},{"issue":"9286","key":"10.1016\/j.ecl.2007.07.001_bib5","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.ecl.2007.07.001_bib6","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ecl.2007.07.001_bib7","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0016-5085(03)00394-9","article-title":"Side effects of therapy for chronic hepatitis C","volume":"124","author":"Russo","year":"2003","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.ecl.2007.07.001_bib8","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1210\/jcem-63-5-1086","article-title":"Thyroid autoimmunity in patients on long-term therapy with leukocyte-derived interferon","volume":"63","author":"Burman","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"issue":"8438","key":"10.1016\/j.ecl.2007.07.001_bib9","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S0140-6736(85)92475-4","article-title":"Primary hypothyroidism associated with interferon therapy of breast cancer","volume":"1","author":"Fentiman","year":"1985","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ecl.2007.07.001_bib10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1089\/105072503322238809","article-title":"Interferon alpha and autoimmune thyroid disease","volume":"13","author":"Prummel","year":"2003","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.ecl.2007.07.001_bib11","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1089\/thy.1997.7.891","article-title":"Interferon alpha-induced thyroid dysfunction: three clinical presentations and a review of the literature","volume":"7","author":"Koh","year":"1997","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.ecl.2007.07.001_bib12","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0002-9343(96)00259-8","article-title":"Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon alpha","volume":"101","author":"Roti","year":"1996","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.ecl.2007.07.001_bib13","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/BF03345087","article-title":"Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type 1 interferons for HCV-related chronic hepatitis: a prospective study","volume":"25","author":"Mazziotti","year":"2002","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"10.1016\/j.ecl.2007.07.001_bib14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1089\/105072502760258730","article-title":"Graves' ophthalmopathy associated with interferon alpha treatment for hepatitis C","volume":"12","author":"Villanueva","year":"2002","journal-title":"Thyroid"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2007.07.001_bib15","first-page":"221","article-title":"Thyroid gland dysfunctions during antiviral therapy of chronic hepatitis C","volume":"7","author":"Kryczka","year":"2001","journal-title":"Med Sci Monit"},{"issue":"4","key":"10.1016\/j.ecl.2007.07.001_bib16","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.21146","article-title":"The clinical and physiological spectrum of interferon alpha-induced thyroiditis: toward a new classification","volume":"43","author":"Mandac","year":"2006","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ecl.2007.07.001_bib17","first-page":"399","article-title":"The risk factor for development of thyroid disease during interferon alpha therapy for chronic hepatitis C","volume":"89","author":"Watanabe","year":"1994","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.ecl.2007.07.001_bib18","first-page":"49","article-title":"Hashimoto's disease during interferon alpha therapy in a patient with pretreatment-negative antithyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease","volume":"22","author":"Martocchia","year":"2001","journal-title":"Neuro Endocrinol Lett"},{"issue":"6","key":"10.1016\/j.ecl.2007.07.001_bib19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-2265.1993.tb02423.x","article-title":"Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C","volume":"39","author":"Baudin","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"10.1016\/j.ecl.2007.07.001_bib20","first-page":"1925","article-title":"Long-term outcome of interferon alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment","volume":"86","author":"Carella","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2007.07.001_bib21","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1530\/eje.0.1320587","article-title":"Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a","volume":"132","author":"Preziati","year":"1995","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2007.07.001_bib22","first-page":"922","article-title":"Autoimmune endocrine disease induced by recombinant interferon alpha therapy for chronic active type C hepatitis","volume":"80","author":"Imagawa","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2007.07.001_bib23","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2265.2002.01553.x","article-title":"Thyrotoxicosis induced by alpha interferon therapy in chronic viral hepatitis","volume":"56","author":"Wong","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"10.1016\/j.ecl.2007.07.001_bib24","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/0016-5085(92)90348-3","article-title":"Development of thyroid disease during therapy of chronic viral hepatitis with interferon alpha","volume":"102","author":"Lisker-Melman","year":"1992","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.ecl.2007.07.001_bib25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/jcem.87.2.8182","article-title":"Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)","volume":"87","author":"Hollowell","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2007.07.001_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2265.1995.tb01894.x","article-title":"The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey","volume":"43","author":"Vanderpump","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"10.1016\/j.ecl.2007.07.001_bib27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2265.1996.751768.x","article-title":"Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon alpha therapy","volume":"44","author":"Marazuela","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ecl.2007.07.001_bib28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0006-291X(88)81072-6","article-title":"Existence of antithyroglobulin IgG in healthy subjects","volume":"155","author":"Kohno","year":"1988","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ecl.2007.07.001_bib29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0090-1229(85)90146-1","article-title":"A high prevalence of thyroglobulin autoantibodies in adults with and without thyroid disease as measured with a sensitive solid-phase immunosorbent radioassay","volume":"37","author":"Ericsson","year":"1985","journal-title":"Clin Immunol Immunopathol"},{"issue":"3","key":"10.1016\/j.ecl.2007.07.001_bib30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000184606","article-title":"Longitudinal study of antibodies against thyroid in patients undergoing interferon alpha therapy for HCV chronic hepatitis","volume":"44","author":"Carella","year":"1995","journal-title":"Horm Res"},{"issue":"4","key":"10.1016\/j.ecl.2007.07.001_bib31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10238-004-0026-3","article-title":"Thyroid autoimmunity and dysfunction associated with type I interferon therapy","volume":"3","author":"Monzani","year":"2004","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.ecl.2007.07.001_bib32","first-page":"399","article-title":"Etiology, pathogenesis, and clinical aspects of thyroiditis","volume":"13","author":"Volpe","year":"1978","journal-title":"Pathol Annu"},{"key":"10.1016\/j.ecl.2007.07.001_bib33","first-page":"1","article-title":"Persistent thyroid autoimmunity after subacute thyroiditis","volume":"23","author":"Weetman","year":"1987","journal-title":"J Clin Lab Immunol"},{"issue":"5","key":"10.1016\/j.ecl.2007.07.001_bib34","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1046\/j.1365-2893.2000.00247.x","article-title":"Subacute thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus","volume":"7","author":"Parana","year":"2000","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.ecl.2007.07.001_bib35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0168-8278(96)80113-9","article-title":"Side effects of high-dose interferon therapy for chronic hepatitis C","volume":"25","author":"Okanoue","year":"1996","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.ecl.2007.07.001_bib36","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.autrev.2004.03.003","article-title":"Interferon-induced autoimmune thyroid disease (AITD): a model for human autoimmunity","volume":"3","author":"Oppenheim","year":"2004","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ecl.2007.07.001_bib37","first-page":"107","article-title":"Infection. Thyroid disease and autoimmunity","volume":"14","author":"Tomer","year":"1993","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.ecl.2007.07.001_bib38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.amjmed.2004.04.004","article-title":"Hepatitis C and thyroid autoimmunity: is there a link?","volume":"117","author":"Tomer","year":"2004","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.ecl.2007.07.001_bib39","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/BF03343626","article-title":"Independent expression of serological markers of thyroid autoimmunity and hepatitis virus C infection in the general population: results of a community-based study in northwestern Sardinia","volume":"22","author":"Loviselli","year":"1999","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"10.1016\/j.ecl.2007.07.001_bib40","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/thy.1997.7.421","article-title":"Failure to find an association between hepatitis C\u00a0virus and thyroid autoimmunity","volume":"7","author":"Metcalfe","year":"1997","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.ecl.2007.07.001_bib41","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/0168-8278(95)80216-9","article-title":"Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C virus infection","volume":"22","author":"Boadas","year":"1995","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.ecl.2007.07.001_bib42","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/hep.1840180205","article-title":"High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy","volume":"18","author":"Tran","year":"1993","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ecl.2007.07.001_bib43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1006\/jaut.1999.0360","article-title":"Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case\u2013control study","volume":"14","author":"Ganne-Carrie","year":"2000","journal-title":"J Autoimmun"},{"issue":"13","key":"10.1016\/j.ecl.2007.07.001_bib44","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archinte.158.13.1445","article-title":"Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy","volume":"158","author":"Fernandez-Soto","year":"1998","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.ecl.2007.07.001_bib45","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.amjmed.2004.01.023","article-title":"Thyroid disorders in chronic hepatitis C","volume":"117","author":"Antonelli","year":"2004","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.ecl.2007.07.001_bib46","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0168-8278(05)80228-4","article-title":"Latent autoimmune thyroid disease in patients with chronic HCV hepatitis","volume":"17","author":"Pateron","year":"1993","journal-title":"J Hepatol"},{"key":"10.1016\/j.ecl.2007.07.001_bib47","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2265.1977.tb01340.x","article-title":"The spectrum of thyroid disease in a community: the Whickham survey","volume":"7","author":"Tunbridge","year":"1977","journal-title":"Clin Endocrinol Oxf"},{"issue":"6","key":"10.1016\/j.ecl.2007.07.001_bib48","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1530\/eje.0.1460743","article-title":"The addition of ribavirin to interferon alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism","volume":"146","author":"Carella","year":"2002","journal-title":"Eur J\u00a0Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2007.07.001_bib49","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/thy.2006.16.563","article-title":"Thyroid disorders in chronic hepatitis C virus infection","volume":"16","author":"Antonelli","year":"2006","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.ecl.2007.07.001_bib50","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"issue":"Pt 7","key":"10.1016\/j.ecl.2007.07.001_bib51","first-page":"1631","article-title":"Replication of hepatitis C virus","volume":"81","author":"Bartenschlager","year":"2000","journal-title":"J Gen Virol"},{"issue":"Pt 11","key":"10.1016\/j.ecl.2007.07.001_bib52","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1099\/vir.0.80401-0","article-title":"Genetic diversity and evolution of hepatitis C virus\u201415 years on","volume":"85","author":"Simmonds","year":"2004","journal-title":"J Gen Virol"},{"issue":"1","key":"10.1016\/j.ecl.2007.07.001_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/135965350501000118","article-title":"Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes","volume":"10","author":"Hnatyszyn","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ecl.2007.07.001_bib54","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1530\/eje.0.1420431","article-title":"Virologic factors related to interferon alpha-induced thyroid dysfunction in patients with chronic hepatitis C","volume":"142","author":"Hsieh","year":"2000","journal-title":"Eur J Endocrinol"},{"issue":"7053","key":"10.1016\/j.ecl.2007.07.001_bib55","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nature04078","article-title":"Evasion of intracellular host defense by hepatitis C virus","volume":"436","author":"Gale","year":"2005","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ecl.2007.07.001_bib56","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/hep.21321","article-title":"Hepatitis C virus entry: molecular biology and clinical implications","volume":"44","author":"Barth","year":"2006","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ecl.2007.07.001_bib57","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/hep.21191","article-title":"Host cell responses induced by hepatitis C virus binding","volume":"43","author":"Fang","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ecl.2007.07.001_bib58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1084\/jem.20011124","article-title":"Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein","volume":"195","author":"Crotta","year":"2002","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.ecl.2007.07.001_bib59","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/1521-4141(200101)31:1<166::AID-IMMU166>3.0.CO;2-L","article-title":"Binding of the hepatitis C virus envelope protein E2 to CD81 provides a costimulatory signal for human T cells","volume":"31","author":"Wack","year":"2001","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.ecl.2007.07.001_bib60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hep.21283","article-title":"Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences","volume":"44","author":"Blackard","year":"2006","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ecl.2007.07.001_bib61","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/hep.510280531","article-title":"Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: specific detection of negative-strand viral RNA in various tissues","volume":"28","author":"Laskus","year":"1998","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.ecl.2007.07.001_bib62","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1086\/378643","article-title":"Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism","volume":"188","author":"Munshi","year":"2003","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.ecl.2007.07.001_bib63","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/505708","article-title":"Signal transducer and activator of transcription factor 1 mediates apoptosis induced by hepatitis C virus and HIV envelope proteins in hepatocytes","volume":"194","author":"Balasubramanian","year":"2006","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2007.07.001_bib64","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1086\/429493","article-title":"Molecular mechanism of hepatic injury in coinfection with hepatitis C virus and HIV","volume":"41","author":"Balasubramanian","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"37","key":"10.1016\/j.ecl.2007.07.001_bib65","doi-asserted-by":"crossref","first-page":"35755","DOI":"10.1074\/jbc.M302889200","article-title":"Hepatitis C virus and HIV envelope proteins collaboratively mediate interleukin-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes","volume":"278","author":"Balasubramanian","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ecl.2007.07.001_bib66","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1210\/er.2002-0030","article-title":"Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function","volume":"24","author":"Tomer","year":"2003","journal-title":"Endocr Rev"},{"issue":"5","key":"10.1016\/j.ecl.2007.07.001_bib67","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.1365-2796.2002.00974.x","article-title":"Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy","volume":"251","author":"Dalgard","year":"2002","journal-title":"J Intern Med"},{"issue":"4-6","key":"10.1016\/j.ecl.2007.07.001_bib68","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0960-0760(91)90287-F","article-title":"Sex steroid regulation of autoimmunity","volume":"40","author":"Grossman","year":"1991","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.ecl.2007.07.001_bib69","first-page":"3290","article-title":"Linkage analysis of candidate genes in autoimmune thyroid disease: 2. Selected gender-related genes and the X chromosome","volume":"83","author":"Barbesino","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2\u20134","key":"10.1016\/j.ecl.2007.07.001_bib70","first-page":"161","article-title":"The effects of alpha interferon on the development of autoimmune thyroiditis in the NOD H2h4 mouse","volume":"10","author":"Oppenheim","year":"2003","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.ecl.2007.07.001_bib71","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jaut.2007.02.006","article-title":"The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future","volume":"28","author":"Jacobson","year":"2007","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ecl.2007.07.001_bib72","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1210\/jcem-61-4-735","article-title":"The genetics of Graves' disease: HLA and disease susceptibility","volume":"61","author":"Stenszky","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2007.07.001_bib73","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.gene.6364059","article-title":"Arginine at position 74 of the HLA-DRb1 chain is associated with Graves' disease","volume":"5","author":"Ban","year":"2004","journal-title":"Genes Immun"},{"key":"10.1016\/j.ecl.2007.07.001_bib74","first-page":"41","article-title":"CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population","volume":"80","author":"Yanagawa","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ecl.2007.07.001_bib75","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/hmg\/8.7.1195","article-title":"The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus","volume":"8","author":"Vaidya","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ecl.2007.07.001_bib76","first-page":"1687","article-title":"CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production","volume":"86","author":"Tomer","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2007.07.001_bib77","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.2337\/diabetes.53.11.3020","article-title":"Replication of an association between the lymphoid tyrosine phosphatase locus (LYP\/PTPN22) with type 1 diabetes and evidence for its role as a general autoimmunity locus","volume":"53","author":"Smyth","year":"2004","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.ecl.2007.07.001_bib78","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.1210\/jc.2004-1108","article-title":"The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease","volume":"89","author":"Velaga","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2007.07.001_bib79","doi-asserted-by":"crossref","first-page":"15119","DOI":"10.1073\/pnas.2434175100","article-title":"Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease","volume":"100","author":"Ban","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.ecl.2007.07.001_bib80","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1210\/jc.2004-2148","article-title":"Multiple SNPs in intron 7 of thyrotropin receptor are associated with Graves' disease","volume":"90","author":"Hiratani","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2007.07.001_bib81","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0168-8278(99)80131-7","article-title":"HLA antigens in patients with interferon alpha-induced autoimmune thyroid disorders in chronic hepatitis C","volume":"30","author":"Kakizaki","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.ecl.2007.07.001_bib82","first-page":"926","article-title":"Immune-regulatory gene involvement in the etiology of interferon-induced thyroiditis (IIT)","volume":"16","author":"Jacobson","year":"2006","journal-title":"Thyroid"},{"issue":"5589","key":"10.1016\/j.ecl.2007.07.001_bib83","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1126\/science.1074900","article-title":"Critical role for STAT4 activation by type 1 interferons in the interferon gamma response to viral infection","volume":"297","author":"Nguyen","year":"2002","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.ecl.2007.07.001_bib84","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1089\/107999000750053690","article-title":"Biologic responses to IFN-alpha administration in humans","volume":"20","author":"Corssmit","year":"2000","journal-title":"J Interferon Cytokine Res"},{"issue":"1","key":"10.1016\/j.ecl.2007.07.001_bib85","first-page":"61","article-title":"Expression of ICAM-1, B7.1 and TPO on human thyrocytes induced by IFN-alpha","volume":"112","author":"You","year":"1999","journal-title":"Chin Med J (Engl)"},{"issue":"10","key":"10.1016\/j.ecl.2007.07.001_bib86","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0167-5699(00)01710-2","article-title":"Type I interferons and T helper development","volume":"21","author":"Farrar","year":"2000","journal-title":"Immunol Today"},{"issue":"3","key":"10.1016\/j.ecl.2007.07.001_bib87","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/gast.1997.v112.pm9041265","article-title":"New insights into the mechanisms of interferon alpha: an immunoregulatory and anti-inflammatory cytokine","volume":"112","author":"Tilg","year":"1997","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.ecl.2007.07.001_bib88","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1210\/jc.2005-0093","article-title":"Innate and acquired immune system in patients developing interferon alpha-related autoimmune thyroiditis: a prospective study","volume":"90","author":"Mazziotti","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ecl.2007.07.001_bib89","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1210\/en.2004-0352","article-title":"Signal transducer and activator of transcription (Stat)-6-dependent, but not Stat4-dependent, immunity is required for the development of autoimmunity in Graves' hyperthyroidism","volume":"145","author":"Land","year":"2004","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.ecl.2007.07.001_bib90","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1046\/j.1365-2796.2002.01045.x","article-title":"Is the IFN-alpha-related thyroid autoimmunity an immunologically heterogeneous disease?","volume":"252","author":"Mazziotti","year":"2002","journal-title":"J Intern Med"},{"issue":"7","key":"10.1016\/j.ecl.2007.07.001_bib91","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.4049\/jimmunol.170.7.3522","article-title":"Prevention of autoantibody-mediated Graves'-like hyperthyroidism in mice with IL-4, a Th2 cytokine","volume":"170","author":"Nagayama","year":"2003","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.ecl.2007.07.001_bib92","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2249.1997.269-ce1161.x","article-title":"Effects of interferon alpha (IFN-alpha) administration on leucocytes in healthy humans","volume":"107","author":"Corssmit","year":"1997","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.ecl.2007.07.001_bib93","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF01714980","article-title":"Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha, and interleukin 2","volume":"62","author":"Aulitzky","year":"1991","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.ecl.2007.07.001_bib94","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1046\/j.1365-2249.1996.d01-784.x","article-title":"Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis","volume":"105","author":"Ajjan","year":"1996","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.ecl.2007.07.001_bib95","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1210\/jcem-70-6-1735","article-title":"Inhibition of 125I organification and thyroid hormone release by interleukin-1, tumor necrosis factor alpha, and interferon gamma in human thyrocytes in suspension culture","volume":"70","author":"Sato","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2007.07.001_bib96","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0002-9343(03)00390-5","article-title":"Autoimmune aspects of cytokine and anticytokine therapies","volume":"115","author":"Krause","year":"2003","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.ecl.2007.07.001_bib97","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1073\/pnas.70.10.2785","article-title":"Enhancement by interferon of the expression of surface antigens on murine leukemia L 1210 cells","volume":"70","author":"Lindahl","year":"1973","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.ecl.2007.07.001_bib98","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1210\/jc.2004-1173","article-title":"Type I interferons modulate the expression of thyroid peroxidase, sodium\/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures","volume":"90","author":"Caraccio","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2007.07.001_bib99","unstructured":"Akeno N, Tomer Y. Dissecting the mechanisms of interferon-induced thyroiditis (IIT): direct effects of interferon alpha on thyroid epithelial cells. Presented at the 89th Meeting of the Endocrine Society, Toronto (Canada), June 2, 2007."},{"issue":"10","key":"10.1016\/j.ecl.2007.07.001_bib100","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1345\/aph.1G144","article-title":"Hashimoto encephalopathy with pegylated interferon alpha-2b and ribavirin","volume":"39","author":"Deutsch","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"17","key":"10.1016\/j.ecl.2007.07.001_bib101","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJM200010263431707","article-title":"Graves' disease","volume":"343","author":"Weetman","year":"2000","journal-title":"N Engl J Med"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852907000746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852907000746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:28:29Z","timestamp":1760174909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852907000746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S0889852907000746"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2007.07.001","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon Alpha Treatment and Thyroid Dysfunction","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2007.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}